Swedish Pharma Firm Selects Certara's Software for Drug Discovery | GenomeWeb

Certara said this week that Medivir, a Swedish pharmaceutical company that focuses on infectious diseases such as hepatitis C, has selected its D360 software as its global drug discovery platform.

According to Certara, Medivir will use D360 — an integrated solution for querying, analyzing, and visualizing drug discovery data — to deliver chemical structure and biological assay data and analytic tools to its discovery chemists and biologists based in Stockholm and Cambridge, UK.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.